Hematopoietic Cytokine-mediated FDG Uptake Simulates the Appearance of Diffuse Metastatic Disease on Whole-body PET Imaging
Overview
Authors
Affiliations
FDG-PET is increasingly being used to assess malignant tumors. However, leukocyte colony-stimulating factors (CSFs), which promote the expansion of hematopoietic bone marrow, have also been demonstrated to cause increased bone-marrow FDG uptake. Three hundred FDG-PET studies conducted over a 1-year period were reviewed for diffuse bone-marrow uptake. Elevated bone-marrow uptake on PET was correlated with pathological findings and courses of granulocyte-CSF (G-CSF) therapy. These results demonstrate that G-CSF mediated FDG uptake in bone marrow is often indistinguishable from that caused by disseminated metastatic disease. However, the bone-marrow response to G-CSF decreases rapidly following the last CSF administration. Therefore, FDG-PET in patients receiving G-CSF should be delayed, when possible, until 5 days after the end of G-CSF therapy.
Hematopoietic islands mimicking osteoblastic metastases within the axial skeleton.
Goller S, Erber B, Fink N, Durr H, Knosel T, Ricke J BMC Musculoskelet Disord. 2022; 23(1):448.
PMID: 35550061 PMC: 9097177. DOI: 10.1186/s12891-022-05402-w.
Diffuse vertebral marrow changes at MRI: Multiple myeloma or normal?.
Vande Berg B, Kirchgesner T, Acid S, Malghem J, Vekemans M, Lecouvet F Skeletal Radiol. 2021; 51(1):89-99.
PMID: 34550397 DOI: 10.1007/s00256-021-03886-6.
Horvath L, Seeber A, Uprimny C, Wolf D, Nachbaur D, Kocher F Ther Adv Hematol. 2021; 11:2040620720977613.
PMID: 33425313 PMC: 7758561. DOI: 10.1177/2040620720977613.
Hao B, Zhao L, Luo N, Ruan D, Pang Y, Guo W BMC Cancer. 2018; 18(1):1192.
PMID: 30497426 PMC: 6267895. DOI: 10.1186/s12885-018-5104-0.
Manov J, Roth P, Kuker R Indian J Nucl Med. 2017; 32(4):259-265.
PMID: 29142340 PMC: 5672744. DOI: 10.4103/ijnm.IJNM_56_17.